A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AMLChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 132
- Registration Number
- NCT06563804
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Kansas, Fairway, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 27
- Registration Number
- NCT06188702
- Locations
- 🇺🇸
Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇺🇸Taylor Cancer Research Center, Maumee, Ohio, United States
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: S095024 RDEDrug: S095029 RDEDrug: S095018 Recommended Dose Expansion (RDE)
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 176
- Registration Number
- NCT06162572
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸University of Kansas Medical Center, Lawrence, Kansas, United States
🇺🇸Henry Ford Health, Detroit, Michigan, United States
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Conditions
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 136
- Registration Number
- NCT06127407
- Locations
- 🇧🇷
Instituto Nacional Do Câncer - Inca, Rio De Janeiro, Brazil
🇧🇷Icesp - Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil
🇧🇷Fundação Amaral Carvalho - Jaú/ Sp, Jaú, Brazil
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
- Conditions
- MSI-H/dMMR Gastroesophageal-junction CancerMSI-H/dMMR Gastric Cancer
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06116136
- Locations
- 🇮🇹
A.O.U. Seconda Università Degli Studi Di Napoli, Campania, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumor, Milan, Italy
🇮🇹A.O.U. Pisana-Ospedale Santa Chiara, Pisa, Italy
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
- Conditions
- IDH1-mutant Cholangiocarcinoma
- Interventions
- Drug: Recommended Combination Dose (RCD) of ivosidenib
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05921760
- Locations
- 🇺🇸
UCSF - Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 64
- Registration Number
- NCT05843708
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05159388
- Locations
- 🇪🇸
Hospital Universitario Gregorio, Madrid, Spain
🇦🇺Chris O'Brian Lifehouse, Camperdown, Australia
🇪🇸START, Madrid, Spain